Regenxbio has initiated a second phase 3 pivotal trial investigating RGX-314 in patients with wet age-related macular degeneration, according to a press release.
ASCENT is a multicenter, randomized, active-controlled trial investigating the safety and efficacy of subretinal delivery of RGX-314, a potential one-time gene therapy, in two dose arms, 6.4 × 1010 genomic copies per eye and 1.3 × 1011 genomic copies per eye, compared with intravitreal aflibercept.
“The initiation of ASCENT is an important milestone for the pivotal program for subretinal delivery of RGX-314 in patients with wet